SARS-CoV-2 Infects Human Pancreatic β-Cells and Elicits β-Cell Impairment

Researchers found that the SARS-CoV-2 receptor, ACE2 and related entry factors were expressed in β-cells, with selectively high expression of NRP1.
[Cell Metabolism]
Wu, C.-T., Lidsky, P. V., Xiao, Y., Lee, I. T., Cheng, R., Nakayama, T., Jiang, S., Demeter, J., Bevacqua, R. J., Chang, C. A., Whitener, R. L., Stalder, A. K., Zhu, B., Chen, H., Goltsev, Y., Tzankov, A., Nayak, J. V., Nolan, G. P., Matter, M. S., … Jackson, P. K. (2021). SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment. Cell Metabolism, 0(0). https://doi.org/10.1016/j.cmet.2021.05.013 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

A Neural Basis for Brain Leptin Action on Reducing Type 1 Diabetic Hyperglycemia

Researchers showed that leptin receptor (LepR)-expressing neurons in arcuate (LepRArc) are selectively activated in type-1 diabetes.
[Nature Communications]
Fan, S., Xu, Y., Lu, Y., Jiang, Z., Li, H., Morrill, J. C., Cai, J., Wu, Q., Xu, Y., Xue, M., Arenkiel, B. R., Huang, C., & Tong, Q. (2021). A neural basis for brain leptin action on reducing type 1 diabetic hyperglycemia. Nature Communications, 12(1), 2662. https://doi.org/10.1038/s41467-021-22940-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

SerpinB13 Antibodies Promote β Cell Development and Resistance to Type 1 Diabetes

Investigators showed that inhibiting serpinB13, a cathepsin L protease inhibitor expressed in the pancreatic epithelium, caused in vitro and in vivo cleavage of the extracellular domain of Notch1.
[Science Translational Medicine]
Kryvalap, Y., Jiang, M. L., Kryvalap, N., Hendrickson, C., & Czyzyk, J. (2021). SerpinB13 antibodies promote β cell development and resistance to type 1 diabetes. Science Translational Medicine, 13(588). https://doi.org/10.1126/scitranslmed.abf1587 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Lotus-Root-Shaped Cell-Encapsulated Construct as a Retrieval Graft for Long-Term Transplantation of Human iPSC-Derived β-Cells

Researchers developed a lotus-root-shaped cell-encapsulated construct as a graft that can be retrieved after long-term human-stem-cell-derived pancreatic beta cell transplantation.
[iScience]
Ozawa, F., Nagata, S., Oda, H., Yabe, S. G., Okochi, H., & Takeuchi, S. (2021). Lotus-root-shaped cell-encapsulated construct as a retrieval graft for long-term transplantation of human iPSC-derived β-cells. IScience, 0(0). https://doi.org/10.1016/j.isci.2021.102309 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Endogenous Mitochondrial Double‐Stranded RNA is Not an Activator of the Type I Interferon Response in Human Pancreatic Beta Cells

Researchers suggested that accumulation of endogenous mtdsRNA following degradosome knockdown depended on the proliferative capacity of the cells and was not a mediator of the type I interferon response in human pancreatic beta cells.
[Autoimmunity Highlights]
Coomans de Brachène, A., Castela, A., Musuaya, A. E., Marselli, L., Marchetti, P., & Eizirik, D. L. (2021). Endogenous mitochondrial double‐stranded RNA is not an activator of the type I interferon response in human pancreatic beta cells. Autoimmunity Highlights, 12(1), 6. https://doi.org/10.1186/s13317-021-00148-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Type 1 Diabetes Mellitus: Much Progress, Many Opportunities

While much has been learned about type 1 diabetes (T1D), it is now clear that there is considerable heterogeneity in T1D with regards to genetics, pathology, response to immune-based therapies, clinical course, and susceptibility to diabetes-related complications. This review highlights knowledge gaps and opportunities to improve the understanding of T1D pathogenesis and outlines emerging therapies to treat or prevent T1D and reduce the burden of T1D.
[Journal of Clinical Investigation]
Powers, A. C. (2021). Type 1 diabetes mellitus: much progress, many opportunities. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI142242 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Islet Sympathetic Innervation and Islet Neuropathology in Patients with Type 1 Diabetes

To investigate islet sympathetic innervation in type 1 diabetes (T1D), sympathetic tyrosine hydroxylase axons were analyzed in control non-diabetic organ donors, non-diabetic islet autoantibody-positive individuals, and age-matched persons with T1D.
[Scientific Reports]
Campbell-Thompson, M., Butterworth, E. A., Boatwright, J. L., Nair, M. A., Nasif, L. H., Nasif, K., Revell, A. Y., Riva, A., Mathews, C. E., Gerling, I. C., Schatz, D. A., & Atkinson, M. A. (2021). Islet sympathetic innervation and islet neuropathology in patients with type 1 diabetes. Scientific Reports, 11(1), 6562. https://doi.org/10.1038/s41598-021-85659-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Combined Therapy of Mesenchymal Stem Cells with a GLP-1 Receptor Agonist, Liraglutide, on an Inflammatory-Mediated Diabetic Non-Human Primate Model

The authors assessed the therapeutic potential of co-administration of human clonal mesenchymal stem cells and liraglutide as a glucagon-like peptide-1 agonist in a non-human primate model with streptozotocin-induced diabetes.
[Life Sciences]
Navabi, R., Negahdari, B., Hajizadeh-Saffar, E., Hajinasrollah, M., Jenab, Y., Rabbani, S., Pakzad, M., Hassani, S.-N., Hezavehei, M., Jafari-Atrabi, M., Tahamtani, Y., & Baharvand, H. (2021). Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model. Life Sciences, 119374. https://doi.org/10.1016/j.lfs.2021.119374 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Evolve BioSystems, Inc. Announces the Use of Activated B. infantis EVC001 by International Consortium to Study the Prevention of Type 1 Diabetes in Children

Evolve BioSystems, Inc. announced that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes in genetically predisposed children. The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries.
[Evolve BioSystems, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes

ViaCyte, Inc. and W. L. Gore & Associates, Inc. announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte’s portfolio of product candidates for the treatment of diabetes.
[ViaCyte, Inc. (PR Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

JDRF Announces New Center of Excellence in New England to Advance Type 1 Diabetes Research

JDRF announced, in collaboration with the Harvard Stem Cell Institute, the launch of the JDRF Center of Excellence in New England.
[JDRF (PR Newswire, LLC)]
Press Release
Bookmark

No account yet? Register

0
Share
Share